Cargando…
Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
BACKGROUND: Despite the universal use of the two-dose trivalent measles-mumps-rubella (MMR) vaccine in the past two decades, outbreaks of these diseases still occur in countries with high vaccine uptake, giving rise to concerns about primary and secondary failure of MMR vaccine components. We aimed...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665966/ https://www.ncbi.nlm.nih.gov/pubmed/32888410 http://dx.doi.org/10.1016/S1473-3099(20)30442-4 |
_version_ | 1784831396731158528 |
---|---|
author | Schenk, Julie Abrams, Steven Theeten, Heidi Van Damme, Pierre Beutels, Philippe Hens, Niel |
author_facet | Schenk, Julie Abrams, Steven Theeten, Heidi Van Damme, Pierre Beutels, Philippe Hens, Niel |
author_sort | Schenk, Julie |
collection | PubMed |
description | BACKGROUND: Despite the universal use of the two-dose trivalent measles-mumps-rubella (MMR) vaccine in the past two decades, outbreaks of these diseases still occur in countries with high vaccine uptake, giving rise to concerns about primary and secondary failure of MMR vaccine components. We aimed to provide seroconversion and waning rate estimates for the measles, mumps, and rubella components of MMR vaccines. METHODS: In this systematic review and meta-analysis we searched PubMed (including MEDLINE), Web of Science, and Embase for randomised controlled trials, cohort studies, or longitudinal studies reporting the immunogenicity and persistence of MMR vaccines, published in English from database inception to Dec 31, 2019. Studies were included if they investigated vaccine-induced immunity in healthy individuals who received a trivalent MMR vaccine, including different dosages and timepoints of vaccine administration. Studies featuring coadministration of MMR with other vaccines, maternal immunity to the MMR vaccine, or non-trivalent formulations of the vaccine were excluded. Pooled seroconversion and waning rates were estimated by random-effects meta-analyses. This study is registered with PROSPERO, CRD42019116705. FINDINGS: We identified 3615 unique studies, 62 (1·7%) of which were eligible for analysis. Estimated overall seroconversion rates were 96·0% (95% CI 94·5–97·4; I(2)=91·1%) for measles, 93·3% (91·1–95·2; I(2)=94·9%) for mumps when excluding the Rubini strain, 91·1% (87·4–94·1; I(2)=96·6%) for mumps when including the Rubini strain, and 98·3% (97·3–99·2; I(2)=93·0%) for rubella. Estimated overall annual waning rates were 0·009 (95% CI 0·005–0·016; I(2)=85·2%) for measles, 0·024 (0·016–0·039; I(2)=94·7%) for mumps, and 0·012 (0·010–0·014; I(2)=93·3%) for rubella. INTERPRETATION: Our meta-analysis provides estimates of primary and secondary vaccine failure, which are essential to improve the accuracy of mathematical and statistical modelling to understand and predict the occurrence of future measles, mumps, and rubella outbreaks in countries with high vaccine uptake. FUNDING: European Research Council. |
format | Online Article Text |
id | pubmed-9665966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96659662022-11-16 Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis Schenk, Julie Abrams, Steven Theeten, Heidi Van Damme, Pierre Beutels, Philippe Hens, Niel Lancet Infect Dis Articles BACKGROUND: Despite the universal use of the two-dose trivalent measles-mumps-rubella (MMR) vaccine in the past two decades, outbreaks of these diseases still occur in countries with high vaccine uptake, giving rise to concerns about primary and secondary failure of MMR vaccine components. We aimed to provide seroconversion and waning rate estimates for the measles, mumps, and rubella components of MMR vaccines. METHODS: In this systematic review and meta-analysis we searched PubMed (including MEDLINE), Web of Science, and Embase for randomised controlled trials, cohort studies, or longitudinal studies reporting the immunogenicity and persistence of MMR vaccines, published in English from database inception to Dec 31, 2019. Studies were included if they investigated vaccine-induced immunity in healthy individuals who received a trivalent MMR vaccine, including different dosages and timepoints of vaccine administration. Studies featuring coadministration of MMR with other vaccines, maternal immunity to the MMR vaccine, or non-trivalent formulations of the vaccine were excluded. Pooled seroconversion and waning rates were estimated by random-effects meta-analyses. This study is registered with PROSPERO, CRD42019116705. FINDINGS: We identified 3615 unique studies, 62 (1·7%) of which were eligible for analysis. Estimated overall seroconversion rates were 96·0% (95% CI 94·5–97·4; I(2)=91·1%) for measles, 93·3% (91·1–95·2; I(2)=94·9%) for mumps when excluding the Rubini strain, 91·1% (87·4–94·1; I(2)=96·6%) for mumps when including the Rubini strain, and 98·3% (97·3–99·2; I(2)=93·0%) for rubella. Estimated overall annual waning rates were 0·009 (95% CI 0·005–0·016; I(2)=85·2%) for measles, 0·024 (0·016–0·039; I(2)=94·7%) for mumps, and 0·012 (0·010–0·014; I(2)=93·3%) for rubella. INTERPRETATION: Our meta-analysis provides estimates of primary and secondary vaccine failure, which are essential to improve the accuracy of mathematical and statistical modelling to understand and predict the occurrence of future measles, mumps, and rubella outbreaks in countries with high vaccine uptake. FUNDING: European Research Council. Elsevier Ltd. 2021-02 2020-09-01 /pmc/articles/PMC9665966/ /pubmed/32888410 http://dx.doi.org/10.1016/S1473-3099(20)30442-4 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Articles Schenk, Julie Abrams, Steven Theeten, Heidi Van Damme, Pierre Beutels, Philippe Hens, Niel Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title | Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title_full | Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title_fullStr | Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title_full_unstemmed | Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title_short | Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
title_sort | immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665966/ https://www.ncbi.nlm.nih.gov/pubmed/32888410 http://dx.doi.org/10.1016/S1473-3099(20)30442-4 |
work_keys_str_mv | AT schenkjulie immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis AT abramssteven immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis AT theetenheidi immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis AT vandammepierre immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis AT beutelsphilippe immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis AT hensniel immunogenicityandpersistenceoftrivalentmeaslesmumpsandrubellavaccinesasystematicreviewandmetaanalysis |